Resources

2018 Global Haemophilia Advocacy Leadership, Budapest, Hungary

January 22, 2018

  • Assessing Innovation as Part of Stakeholder Communications
    • Learning from the coreHEM Project  

    Scientific and Academic Coagulation Consortium, Old Windsor, UK

    January 10 & 11, 2018

  • New Frontiers in Coagulation Medicine
    • PK/Inhibitors: How to Interpret in Hemophilia  

    ASH - 59th Annual Meeting & Exposition, Atlanta, Georgia

    Dcember 9-12, 2017

    • Using Pharmacokinetics to Individualize Hemophilia Therapy  

    McMaster University - Continuing Health Sciences Education

    November 2017

  • Persistent Post-Surgical Pain - A Model for the Study of Chronic Pain.
    • How HiRU Might Support Chronic Pain Research  

    ISTH 2017 Congress, Berlin, Germany

    July 8-13, 2017

  • What is an Achievable Trough with Current Products and at What Cost?  

  • Working Group on Pharmacokinetics and Population Pharmacokinetics  

    • Canadian Hemophilia Society - Rendez-Vous 2017, Toronto, Canada

    May 25-28, 2017

  • The NHF-McMaster Guidelines on Models of Care in Hemophilia  

  • CBDR Report  

    • XXXth International Symposium on Technical Innovations in Laboratory Hematology (Webinar)

    May 4-6, 2017

  • Using Evidence for Hematology Laboratory Practice  

    • 10th Annual Congress of EAHAD, Paris, France

    February 1-3, 2017

  • How Important is PK?  

    • RARE Best Practice Conference 2016, Rome, Italy

    November 24, 2016

  • Catastrophic Antiphospholipid Syndrome (CAPS) and Models of Care for Hemophilia Clinical Practice Guidelines: Lessons Learnt  

    • Bayer Hematology Conference 2016, Madrid, Spain (Conference Chair)

    November 3-5, 2016

  • Connecting Pharmacokinetics and Phenotypes to Tailored Hemophilia Treatment  

    • 24th Cochrane Colloquium, Seoul, South Korea

    October 23-27, 2016

  • GRADE for Overall Prognosis  

    • World Federation of Hemophilia 2016 World Congress, Orlando, Florida

    July 24-28, 2016

  • What is good quality data?  

  • Managing Inhibitor Risk in Both PUPs and PTPs  

  • Current Adverse Events Reporting in Hemophilia  

  • Evidence-Based Guidance on Comprehensive Care for Hemophilia  

    • The 62nd Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis, Montpellier, France

    May 25 - 28, 2016

  • Working Group on Pharmacokinetics and Population Pharmacokinetics of Factor Concentrates  

  • Working Group on Reporting Guidelines on Inhibitor Cases in Previously Treated Hemophilia Patients  

    • 2016 Bi-Regional Annual Conference, Mountain and Western States Regional Hemophilia Treatment Centers, Scottsdale, Arizona, USA

    April 24-25, 2016

  • Evidence Based Practice  

    • Transfusion Medicine Resident Education Seminar (Webinar)

    April 19, 2016

  • EBManagement of hemophilia: Building the blocks for compative EBME effectiveness in Canada and beyond: CBDR, CHESS, WAPPS, and PROBE  

    • Frühjahrsforum Hämophilie 2016, Bonn, Germany

    April 15-16, 2016

  • Population-based PK in haemophilia A  

    • EAHAD 2016 - 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden

    February 1 - 5, 2016

  • Evidence-Based Haemophilia Care - Current Status and Where To Go? 

    • The 9th WFH Global Forum on Research and Treatment Products for Bleeding Disorders, Montreal, Canada

    October 22-23, 2015

  • How to measure progress in the provision of care for hemophilia  

    • XXIII Cochrane Colloquium, Vienna, Austria

    October 3-7, 2015

  • GRADE: the past 15 and next…years. GRADE for Prognostic Evidence  

    • Hemophilia Federation of Australia XVII Meeting, Gold Coast, Australia

    October 1-2, 2015

  • Risk factors for inhibitor development: any clinical role?  

  • An Interview with A/Professor Alfonso Iorio – The International Perspective  

    • ISTH 2015 Congress: Reaching for Unprecedented Peaks, Toronto, Canada

    June 20-25, 2015

  • Inhibitor reporting standardization in previously treated patients  

  • WAPPS project (Web Accessible Population Pharmacokinetics Service)  

  • A population approach to hemophilia pharmacokenetics. WAPPS: a web-service for bayesian post hoc estimation 

    • XXVIIIth International Symposium on Technological Innovations in Laboratory Hematology, Chicago, Illinois

    May 19-21, 2015

  • Using evidence for hematology laboratory practice  

    • XIV International Muscoloskeletal Meeting, World Federation of Hemophilia, Belfast, Ireland

    May 7-9, 2015

  • Study design: A critical aspect of research  

    • Internal seminar given at FDA, Washington, DC

    April 27, 2015

  • Implementation of a population pharmacokinetic approach to individual PK estimation to tailor treatment in hemophilia patients  

    • Hemophilia Research Study Update, Berlin, Germany

    March 12-14, 2015

  • Balancing risk factors for inhibitors development in clinical practice  

    • EHC Round Table on Factor Concentrate-Related Inhibitor Risk in Haemophilia A, Brussels, Belgium

    March 2, 2015

  • Critical appraisal of inhibitor in PUP data  

    • 8th Annual Congress of the European Association of Haemophilia and Allied Disorders, Helsinki, Finland

    February 11-13, 2015

  • Population pharmacokinetics for busy clinicians and active patients: how to get the most out of it?  

  • Inhibitor development according to FVIII concentrate in PUPs: how to interpret current evidence?  

  • Advances in Technology: How can we Assess the Potential, and then Confirm the Reality  

    • 56th American Society of Hematology Annual Meeting & Exposition at Moscone Center, San Francisco, CA.

    December 6-9, 2014

  • ASH Poster - PK characteristics for FVIII and FIX    

    • Presentations at the Convegno Triennale AICE at Florence, Italy

    November 4, 2014

  • WAPPS - Web-based Application for a Population Pharmacokinetic Service  

    • Presentations at the Ministry of Health 2014 at Parsian Azadi Hotel-Tehran-Iran

    October 23, 2014

  • Guidelines and Priorities for safe Switching between plasma derived and recombinant Factor VIII.   

  • Comparison studies on safety and efficacy different generations of recombinant products.  
    • Presentations at the World Federation of Hemophilia 2014 World Congress at Melbourne, Australia

    May 11-15, 2014

  • Non-adherence and its impact on treatment efficacy.   

  • Assessment of long term safety and efficacy of clotting factor concentrates.  

  • Real-World Prophylaxis Experience: Perspectives from Clinical Practice.  

  • An Indirect Comparison of the Efficacy of Prophylactic Use of rFIXFc and rFIX Products and Simulation of the Effect of Compliance on Effectiveness.  

  • ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method]Safety and effectiveness: 10 years of clinical experience.  

    • Top